Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)

BACKGROUND: S0931 is assessing recurrence-free survival in renal cell carcinoma (RCC) patients randomized to receive everolimus (EVE) versus placebo for one year following nephrectomy. Due to a higher than expected dropout rate, we assessed EVE trough levels in the adjuvant setting to evaluate the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Synold, Timothy W., Plets, Melissa, Tangen, Catherine M., Heath, Elisabeth I., Palapattu, Ganesh S., Mack, Philip C., Stein, Mark N., Meng, Maxwell V., Lara, Primo, Vogelzang, Nicholas J., Thompson, Ian Murchie, Ryan, Christopher W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864417/
https://www.ncbi.nlm.nih.gov/pubmed/31763512
http://dx.doi.org/10.3233/KCA-180049

Ejemplares similares

Ejemplares similares